✦ LIBER ✦

Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study

✍ Scribed by Bella Kaufman; Maureen Trudeau; Ahmad Awada; Kimberly Blackwell; Thomas Bachelot; Vanessa Salazar; Michelle DeSilvio; Ronald Westlund; Tal Zaks; Neil Spector; Stephen Johnston

Book ID: 117784994
Publisher: The Lancet
Year: 2009
Tongue: English
Weight: 500 KB
Volume: 10
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(09)70087-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Final results of a multicenter phase II

Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

✍ Marta Pestrin, Silvia Bessi, Fabio Puglisi, Alessandro M. Minisini, Giovanna Mas 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 246 KB

Results of a phase II study of liposomal

Results of a phase II study of liposomal doxorubicin (Myocet®) in combination with weekly paclitaxel and trastuzumab (Herceptin®) In patients with HER2-positive locally advanced or metastatic breast cancer (LA/MBC)

✍ J Baselga; M.A Climent; A Lluch; J Hornedo; P Gascon; A.T Sanchez; V Guillem; H 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 173 KB